NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CHRO

Channel Therapeutics Corporation

May 16 • 04:00PM ET

1.00

Dollar change +0.04
Percentage change 4.17	%

Healthcare • Biotechnology • USA • AMEX

Peers: VRTX BMRN SRPT BLUE ALNY IONS NBIX AMGN GILD REGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.73	Insider Own	86.60%	Shs Outstand	5.82M	Perf Week	-9.09%
Market Cap	6.60M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.88M	Perf Month	-20.32%
Income	-10.07M	PEG	-	EPS next Q	-	Inst Own	9.57%	Short Float	17.77%	Perf Quarter	-46.81%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-46.69%	Short Ratio	0.22	Perf Half Y	57.31%
Book/sh	-0.25	P/B	-	EPS next Y	-	ROA	-931.05%	Short Interest	0.16M	Perf Year	-53.92%
Cash/sh	0.19	P/C	5.28	EPS next 5Y	-	ROE	-	52W Range	0.45 - 3.80	Perf YTD	56.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-73.68%	Beta	3.35
Dividend TTM	-	Quick Ratio	0.39	Sales past 5Y	-	Gross Margin	-	52W Low	122.22%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	0.39	EPS Y/Y TTM	-144.62%	Oper. Margin	-	RSI (14)	37.32	Volatility	13.19% 15.85%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-18.70%	Payout	-	Rel Volume	0.05	Prev Close	0.96
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	698.90K	Price	1.00
SMA20	-17.18%	SMA50	-28.23%	SMA200	-10.47%	Trades		Volume	35,604	Change	4.17%

Today 10:20AM	Trump Trade: Trump asks Apple to stop building iPhone plants in India (TipRanks)
May-14-25 08:00AM	Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models (GlobeNewswire)
07:59AM	EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models (Benzinga)
May-01-25 05:00PM	Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules (GlobeNewswire) +9.65%
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire) +46.61%
05:45AM	Loading…
05:45AM	EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity (Benzinga)
Apr-04-25 09:35AM	Roches Genentech present data on trontinemab, Elecsys plasma test (TipRanks)
Dec-20-24 09:00AM	Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine (GlobeNewswire)
Dec-18-24 08:30AM	Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model (GlobeNewswire)
Nov-21-24 09:49AM	Chromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates (GlobeNewswire)
Oct-29-24 08:30AM	Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain (GlobeNewswire) +6.80%
Oct-28-24 08:00AM	Chromocell to Present at Upcoming Fall Investor Conferences (GlobeNewswire) -10.42%
Oct-24-24 08:45AM	Chromocell Announces Amendment to Stock Repurchase Plan (GlobeNewswire) +13.10%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) -8.16%
08:35AM	Loading…
08:35AM	Chromocell to Participate in Life Sciences Investor Forum September 19th (GlobeNewswire)
Sep-03-24 09:00AM	Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -8.60%
Aug-07-24 08:45AM	Chromocell Announces Stock Repurchase Plan (GlobeNewswire)
Jul-15-24 09:00AM	Chromocell to Participate in the Virtual Investor Lunch Break Series (GlobeNewswire)
May-13-24 09:00AM	Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024 (GlobeNewswire) +38.25%
Apr-09-24 08:30AM	Chromocell Issues Letter to Stockholders from Chief Executive Officer (GlobeNewswire) -8.37%
Mar-21-24 08:30AM	Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler (GlobeNewswire)
Mar-18-24 10:00AM	Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 (GlobeNewswire) -5.44%
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
Mar-11-24 09:00AM	Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 (GlobeNewswire) -6.31%
Feb-27-24 08:00AM	Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions (GlobeNewswire)
Feb-21-24 04:47PM	Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million (GlobeNewswire)
Feb-16-24 08:00AM	Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering (GlobeNewswire)

Channel Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of therapeutics. It focuses on non-opioid therapy of chronic eye pain. The company was founded in 2002 and is headquartered in Freehold, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Malamut Richard	Director	Sep 12 '24	Buy	0.94	10,400	9,825	91,565	Sep 16 04:56 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 13 '24	Buy	0.97	3,500	3,395	547,710	Sep 16 04:55 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 12 '24	Buy	0.97	1,700	1,649	544,210	Sep 16 04:55 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 10 '24	Buy	0.89	6,500	5,785	537,010	Sep 12 05:35 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 11 '24	Buy	0.94	5,500	5,170	542,510	Sep 12 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CHRO

Channel Therapeutics Corporation

Upgrade your FINVIZ experience